They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO
Can a preclinical biotech with grand ambitions, a star scientific founder and enthusiastic backers with deep pockets fly a big IPO against the gale force headwinds we’ve seen this year?
In this economy?
The people at Prime Medicine, which bills itself as a CRISPR 3.0 play, aim to find out if they can buck the trend — which has relented enough to allow for one upsized biotech IPO to get through — and possibly help pry open a window that was slammed shut at the beginning of the year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.